Mihails Šatcs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mihails Šatcs has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Edvins Miklasevics
Faculty of Medicine, Riga Stradins University, LV-1007 Riga, Latvia
3 shared publications - Miki Nakazawa
Institute of Oncology and Molecular Genetics, Riga Stradins University, Pilsonu Street 13, Block 13, LV-1002 Riga, Latvia
3 shared publications - Zanda Daneberga
Institute of Oncology and Molecular Genetics, Rīga Stradiņš University, Riga, Latvia
3 shared publications - Janis Gardovskis
Department of Surgery, Riga Stradins University, Dzirciema Street 16, LV-1007 Riga, Latvia
2 shared publications - Andris Gardovskis
Riga Stradins University, Latvia
1 shared publication - Arvids Irmejs
Pauls Stradiņš Clinical University Hospital, Pilsoņu iela 13, LV-1002 Riga, Latvia
1 shared publication
Latest Publications
- Open Access
- 14 August 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (16) , 2037
The Transcriptomic Profile Underlying Somatic Monoallelic BRCA1 Inactivation: A Biomarker for Breast Cancer Prognosis
Background and Objectives: Most of the research on the role of the BRCA1 gene in breast cancer is focused on monoallelic germline alterations and loss of heterozygosity in tumors. The aim of this study was to identify the characteristic transcriptomic pattern of monoallelic somatic BRCA1 inactivation and estimate its correlation with event-free breast cancer survival. Materials and Methods: We conducted global transcriptome sequencing of breast cancer tissue samples to identify differentially expressed genes and signaling pathways associated with monoallelic somatic BRCA1 inactivation. The study group involved 36 patient samples categorized based on BRCA1 inactivation status. Subsequently, the differential gene expression and Kaplan-Meier analyses in the groups with and without monoallelic somatic BRCA1 inactivation were performed. Results: Kaplan-Meier analysis showed a tendency for longer event-free survival in patients with monoallelic somatic BRCA1 inactivation, suggesting somatic BRCA1 inactivation to be a favorable prognostic. Differential gene expression analysis followed by the STRING tool enrichment analysis showed significant enrichment of proteins in the extracellular region and extracellular space. Conclusions: In this study, we identified transcriptomic profiles of differentially expressed genes TPSD1, FABP4, CARTPT, and MMP9 as indicative of homologous recombination-impaired tumors with a tendency for better therapy results.
- 14 August 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (16) , 2037
Open AccessThe Transcriptomic Profile Underlying Somatic Monoallelic BRCA1 Inactivation: A Biomarker for Breast Cancer Prognosis
Background and Objectives: Most of the research on the role of the BRCA1 gene in breast cancer is focused on monoallelic germline alterations and loss of heterozygosity in tumors. The aim of this study was to identify the characteristic transcriptomic pattern of monoallelic somatic BRCA1 inactivation and estimate its correlation with event-free breast cancer survival. Materials and Methods: We conducted global transcriptome sequencing of breast cancer tissue samples to identify differentially expressed genes and signaling pathways associated with monoallelic somatic BRCA1 inactivation. The study group involved 36 patient samples categorized based on BRCA1 inactivation status. Subsequently, the differential gene expression and Kaplan-Meier analyses in the groups with and without monoallelic somatic BRCA1 inactivation were performed. Results: Kaplan-Meier analysis showed a tendency for longer event-free survival in patients with monoallelic somatic BRCA1 inactivation, suggesting somatic BRCA1 inactivation to be a favorable prognostic. Differential gene expression analysis followed by the STRING tool enrichment analysis showed significant enrichment of proteins in the extracellular region and extracellular space. Conclusions: In this study, we identified transcriptomic profiles of differentially expressed genes TPSD1, FABP4, CARTPT, and MMP9 as indicative of homologous recombination-impaired tumors with a tendency for better therapy results.
- Open Access
- 18 February 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (4) , 492
Liquid Biopsy Based Bladder Cancer Diagnostic by Machine Learning
Background/Objectives: The timely diagnostics of bladder cancer is still a challenge in clinical settings. The reliability of conventional testing methods does not reach desirable accuracy and sensitivity, and it has an invasive nature. The present study examines the application of machine learning to improve bladder cancer diagnostics by integrating miRNA expression levels, demographic routine laboratory test results, and clinical data. We proposed that merging these datasets would enhance diagnostic accuracy. Methods: This study combined molecular biology methods for liquid biopsy, routine clinical data, and application of machine learning approach for the acquired data analysis. We evaluated urinary exosome miRNA expression data in combination with patient test results, as well as clinical and demographic data using three machine learning models: Random Forest, SVM, and XGBoost classifiers. Results: Based solely on miRNA data, the SVM model achieved an ROC curve area of 0.75. Patient analysis’ clinical and demographic data obtained ROC curve area of 0.80. Combining both data types enhanced performance, resulting in an F1 score of 0.79 and an ROC of 0.85. The feature importance analysis identified key predictors, including erythrocytes in urine, age, and several miRNAs. Conclusions: Our findings indicate the potential of a multi-modal approach to improve the accuracy of bladder cancer diagnosis in a non-invasive manner.
- 18 February 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (4) , 492
Open AccessLiquid Biopsy Based Bladder Cancer Diagnostic by Machine Learning
Background/Objectives: The timely diagnostics of bladder cancer is still a challenge in clinical settings. The reliability of conventional testing methods does not reach desirable accuracy and sensitivity, and it has an invasive nature. The present study examines the application of machine learning to improve bladder cancer diagnostics by integrating miRNA expression levels, demographic routine laboratory test results, and clinical data. We proposed that merging these datasets would enhance diagnostic accuracy. Methods: This study combined molecular biology methods for liquid biopsy, routine clinical data, and application of machine learning approach for the acquired data analysis. We evaluated urinary exosome miRNA expression data in combination with patient test results, as well as clinical and demographic data using three machine learning models: Random Forest, SVM, and XGBoost classifiers. Results: Based solely on miRNA data, the SVM model achieved an ROC curve area of 0.75. Patient analysis’ clinical and demographic data obtained ROC curve area of 0.80. Combining both data types enhanced performance, resulting in an F1 score of 0.79 and an ROC of 0.85. The feature importance analysis identified key predictors, including erythrocytes in urine, age, and several miRNAs. Conclusions: Our findings indicate the potential of a multi-modal approach to improve the accuracy of bladder cancer diagnosis in a non-invasive manner.
- Open Access
- 13 January 2025
- Published by MDPI AG in Preprints.org
The Predictive Role of microRNA 142–5p, microRNA 182–3p, and microRNA 99a-3p in Disease-Free Survival and Overall Survival in Patients with Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiation Therapy and Radical Surgery
Background/Objectives: MicroRNAs (miRNAs) are likely to play a significant role in the prediction of rectal cancer response to chemoradiation therapy, offering insights that complement other biological tumour markers. The study aimed to perform miRNA profiling in rectal cancer tissues in patients with good (GR) and bad response (BR) to neoadjuvant chemoradiation therapy (nCRT), select the potentially clinically relevant ones, and further evaluate their relationship with subsequent disease outcomes and survival prognosis. Methods: A total of 40 selected patients with locally advanced rectal cancer who received nCRT and following surgical treatment in the period from 2016 to 2021 were involved. Two study groups were created – GR and BR according to the Dworak tumour regression grading (TRG) system. The identification of 752 miRNAs was conducted in rectal cancer tissue. Results: Six upregulated miRNAs were set as clinically significant within the selected samples and subsequently validated in the BR and GR groups. MiR-142-5p, miR-182-3p, and miR-99a-3p exhibited statistical significance in validation. The results showed that BR to nCRT, lower expression of miRNA-142-5p and miR-99a-3p, and higher expression of miR-182-3p were associated with a trend toward worse local recurrence-free survival, distant metastases-free survival, and overall survival in comparison to GR. Conclusion: MiRNAs may potentially serve as clinical biomarkers in prediction of disease-free survival and overall survival in patients with rectal cancer.
- 13 January 2025
- Published by MDPI AG in Preprints.org
Open AccessThe Predictive Role of microRNA 142–5p, microRNA 182–3p, and microRNA 99a-3p in Disease-Free Survival and Overall Survival in Patients with Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiation Therapy and Radical Surgery
Background/Objectives: MicroRNAs (miRNAs) are likely to play a significant role in the prediction of rectal cancer response to chemoradiation therapy, offering insights that complement other biological tumour markers. The study aimed to perform miRNA profiling in rectal cancer tissues in patients with good (GR) and bad response (BR) to neoadjuvant chemoradiation therapy (nCRT), select the potentially clinically relevant ones, and further evaluate their relationship with subsequent disease outcomes and survival prognosis. Methods: A total of 40 selected patients with locally advanced rectal cancer who received nCRT and following surgical treatment in the period from 2016 to 2021 were involved. Two study groups were created – GR and BR according to the Dworak tumour regression grading (TRG) system. The identification of 752 miRNAs was conducted in rectal cancer tissue. Results: Six upregulated miRNAs were set as clinically significant within the selected samples and subsequently validated in the BR and GR groups. MiR-142-5p, miR-182-3p, and miR-99a-3p exhibited statistical significance in validation. The results showed that BR to nCRT, lower expression of miRNA-142-5p and miR-99a-3p, and higher expression of miR-182-3p were associated with a trend toward worse local recurrence-free survival, distant metastases-free survival, and overall survival in comparison to GR. Conclusion: MiRNAs may potentially serve as clinical biomarkers in prediction of disease-free survival and overall survival in patients with rectal cancer.